BIOMAT Database Logo BIOMAT Database Logo

Low dose alpha interferon treatment in chronic hepatitis B virus infection. 1993

R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Abteilung für Gastroenterologie und Hepatologie, Medizinische Hochschule Hannover, Germany.

Fifty eight patients with chronic viral hepatitis B (HBV) were randomised in a prospectively controlled trial. Thirty patients were treated with 3 million units (MU) of interferon alfa-2b subcutaneously thrice weekly for four months. Twenty eight controls received no treatment. The follow up period after treatment was six months. Twenty eight treated patients and 27 controls completed the protocol. One woman in the treatment group showed a complete response, and eight other treated patients (32%) showed a partial response. Three patients in the control group (11%) lost hepatitis B e antigen and HBV-DNA spontaneously. This finding is statistically significant (p < 0.05). The elimination of HBV markers from the serum was associated with a return to normal of serum aminotransferase activities. Reactivation of hepatitis was not observed after seroconversion.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Chronic hepatitis B virus infection and interferon-alpha.
October 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection.
January 2022, Case reports in infectious diseases,
R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Comment: Alpha-interferon in treating chronic hepatitis B virus infection.
March 1986, Drug intelligence & clinical pharmacy,
R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
[Re-treatment with interferon-alpha in chronic hepatitis B and C virus infection].
February 1995, Zeitschrift fur Gastroenterologie,
R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Hepatic expression of interferon-alpha in chronic hepatitis B virus infection.
September 1994, Digestive diseases and sciences,
R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Response to low-dose interferon in chronic liver disease due to hepatitis B virus infection.
January 1998, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology,
R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment.
November 1995, The Journal of pediatrics,
R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Treatment with low-dose interferon-alpha in Bulgarian HBeAg-negative patients with chronic hepatitis B.
December 1998, Journal of clinical gastroenterology,
R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Low-dose interferon-alpha treatment for feline immunodeficiency virus infection.
February 2006, Veterinary immunology and immunopathology,
R Müller, and R Baumgarten, and R Markus, and M Schulz, and H Wittenberg, and B Hintsche-Kilger, and J D Fengler, and P von Wussow, and H Meisel, and H Klein
Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon.
September 1989, Annals of internal medicine,
Copied contents to your clipboard!